M
Michaela Barbier
Researcher at Novartis
Publications - 6
Citations - 153
Michaela Barbier is an academic researcher from Novartis. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 2, co-authored 2 publications receiving 139 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study.
TL;DR: Support for the BP‐lowering benefits of complementary antihypertensive therapy with amlodipine and valsartan in patients with hypertension uncontrolled by previous monotherapy is provided.
Journal ArticleDOI
Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.
TL;DR: In this single-dose, open-label study, indacaterol 200’µg provided effective 24‐h bronchodilation, with a longer duration than salmeterol 50 µG and a good overall safety profile.
Journal ArticleDOI
Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
Dominik Menges,Henock Yebyo,Sergio Sivec-Muniz,Sarah R. Haile,Michaela Barbier,Yuki Tomonaga,Matthias Schwenkglenks,Milo A. Puhan +7 more
TL;DR: For example, this paper found evidence for a short-term HRQoL decrease lasting 3-6 mo for ADT + docetaxel (moderate certainty), ADT+ enzalutamide (low certainty), and ADT-Abiraterone (high certainty) compared with ADT alone, while no systemic combination treatment showed a clear improvement in health-related quality of life compared with androgen deprivation therapy alone.
Journal ArticleDOI
Colorectal cancer surveillance by colonoscopy in a prospective, population-based long-term Swiss screening study – outcomes, adherence, and costs
TL;DR: The findings suggest that follow-up of screening colonoscopy should be reconsidered in Switzerland; in particular, long-term adherence is critical.
Journal ArticleDOI
Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer
Michaela Barbier,Yuki Tomonaga,Dominik Menges,Henock Yebyo,Sarah R. Haile,Milo A. Puhan,Matthias Schwenkglenks +6 more
TL;DR: In this article , the authors developed a Markov cohort model with health states of progression-free disease, progressive disease and death for men with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) with a 30-year time horizon.